Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5 fluorodeoxyuridine resistant variant of mouse neuroblastoma

F. Baskin, S. C. Carlin, P. Kraus, M. Friedkin, R. N. Rosenberg

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Mechanisms of resistance to chemotherapeutic agents were investigated using mouse neuroblastoma cells grown in tissue culture as an experimental model. The authors report the characterization of a variant which can grow in the presence of 2000 times more 5 fluorodeoxyuridine (FUdR) than the sensitive parent strain. This mutant displays an 8 fold elevation in thymidylate synthetase, but its drug retention and pyrimidine kinase, phosphorylase, and phosphoribosyltransferase activities are identical with those of sensitive cells. Drug retention is temperature dependent, inhibited by thymidine, and blocked by dinitrophenol but not ouabain, suggesting a need for cytoplasmic phosphorylation. Thymidylate synthetase isolated from either sensitive or resistant cells is strongly inhibited by 5 fluorodeoxyuridine 5 phosphate, and thymidine protects cells against the toxic effects of FUdR. Both the resistance of the variant to FUdR and its elevated thymidylate synthetase specific activity are unstable, largely disappearing after 9 wk (63 generations) without drug. Thymidine kinase is responsible for the phosphorylation of FUdR in this cell. Thus this FUdR resistant neuroblastoma line differs from all corresponding mutants in other tumor cell lines.

Original languageEnglish (US)
Pages (from-to)105-117
Number of pages13
JournalMolecular Pharmacology
Volume11
Issue number1
StatePublished - 1975

Fingerprint

Floxuridine
Thymidylate Synthase
Neuroblastoma
Drug Therapy
Pyrimidine Phosphorylases
Thymine Nucleotides
Phosphorylation
Pharmaceutical Preparations
Dinitrophenols
Thymidine Kinase
Poisons
Ouabain
Tumor Cell Line
Thymidine
Theoretical Models
Phosphotransferases
Temperature

ASJC Scopus subject areas

  • Pharmacology

Cite this

Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5 fluorodeoxyuridine resistant variant of mouse neuroblastoma. / Baskin, F.; Carlin, S. C.; Kraus, P.; Friedkin, M.; Rosenberg, R. N.

In: Molecular Pharmacology, Vol. 11, No. 1, 1975, p. 105-117.

Research output: Contribution to journalArticle

@article{2089a6d21a1c47b1b7688b577c922c0f,
title = "Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5 fluorodeoxyuridine resistant variant of mouse neuroblastoma",
abstract = "Mechanisms of resistance to chemotherapeutic agents were investigated using mouse neuroblastoma cells grown in tissue culture as an experimental model. The authors report the characterization of a variant which can grow in the presence of 2000 times more 5 fluorodeoxyuridine (FUdR) than the sensitive parent strain. This mutant displays an 8 fold elevation in thymidylate synthetase, but its drug retention and pyrimidine kinase, phosphorylase, and phosphoribosyltransferase activities are identical with those of sensitive cells. Drug retention is temperature dependent, inhibited by thymidine, and blocked by dinitrophenol but not ouabain, suggesting a need for cytoplasmic phosphorylation. Thymidylate synthetase isolated from either sensitive or resistant cells is strongly inhibited by 5 fluorodeoxyuridine 5 phosphate, and thymidine protects cells against the toxic effects of FUdR. Both the resistance of the variant to FUdR and its elevated thymidylate synthetase specific activity are unstable, largely disappearing after 9 wk (63 generations) without drug. Thymidine kinase is responsible for the phosphorylation of FUdR in this cell. Thus this FUdR resistant neuroblastoma line differs from all corresponding mutants in other tumor cell lines.",
author = "F. Baskin and Carlin, {S. C.} and P. Kraus and M. Friedkin and Rosenberg, {R. N.}",
year = "1975",
language = "English (US)",
volume = "11",
pages = "105--117",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5 fluorodeoxyuridine resistant variant of mouse neuroblastoma

AU - Baskin, F.

AU - Carlin, S. C.

AU - Kraus, P.

AU - Friedkin, M.

AU - Rosenberg, R. N.

PY - 1975

Y1 - 1975

N2 - Mechanisms of resistance to chemotherapeutic agents were investigated using mouse neuroblastoma cells grown in tissue culture as an experimental model. The authors report the characterization of a variant which can grow in the presence of 2000 times more 5 fluorodeoxyuridine (FUdR) than the sensitive parent strain. This mutant displays an 8 fold elevation in thymidylate synthetase, but its drug retention and pyrimidine kinase, phosphorylase, and phosphoribosyltransferase activities are identical with those of sensitive cells. Drug retention is temperature dependent, inhibited by thymidine, and blocked by dinitrophenol but not ouabain, suggesting a need for cytoplasmic phosphorylation. Thymidylate synthetase isolated from either sensitive or resistant cells is strongly inhibited by 5 fluorodeoxyuridine 5 phosphate, and thymidine protects cells against the toxic effects of FUdR. Both the resistance of the variant to FUdR and its elevated thymidylate synthetase specific activity are unstable, largely disappearing after 9 wk (63 generations) without drug. Thymidine kinase is responsible for the phosphorylation of FUdR in this cell. Thus this FUdR resistant neuroblastoma line differs from all corresponding mutants in other tumor cell lines.

AB - Mechanisms of resistance to chemotherapeutic agents were investigated using mouse neuroblastoma cells grown in tissue culture as an experimental model. The authors report the characterization of a variant which can grow in the presence of 2000 times more 5 fluorodeoxyuridine (FUdR) than the sensitive parent strain. This mutant displays an 8 fold elevation in thymidylate synthetase, but its drug retention and pyrimidine kinase, phosphorylase, and phosphoribosyltransferase activities are identical with those of sensitive cells. Drug retention is temperature dependent, inhibited by thymidine, and blocked by dinitrophenol but not ouabain, suggesting a need for cytoplasmic phosphorylation. Thymidylate synthetase isolated from either sensitive or resistant cells is strongly inhibited by 5 fluorodeoxyuridine 5 phosphate, and thymidine protects cells against the toxic effects of FUdR. Both the resistance of the variant to FUdR and its elevated thymidylate synthetase specific activity are unstable, largely disappearing after 9 wk (63 generations) without drug. Thymidine kinase is responsible for the phosphorylation of FUdR in this cell. Thus this FUdR resistant neuroblastoma line differs from all corresponding mutants in other tumor cell lines.

UR - http://www.scopus.com/inward/record.url?scp=0016441651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016441651&partnerID=8YFLogxK

M3 - Article

C2 - 123312

AN - SCOPUS:0016441651

VL - 11

SP - 105

EP - 117

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 1

ER -